Discover 1,244 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,244
A Phase 1/1b Study of IAM1363 in HER2 Cancers
for
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,
Location: Nashville TN, St Louis MO, Chicago IL, Durham NC,
Sponsor: Iambic Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT06253871
Phase1, Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
for
NHL, Multiple Myeloma, Blood Cancer,
Location: Nashville TN, Atlanta GA, Winston-Salem NC,
Sponsor: Indapta Therapeutics, INC.
Sex: All
Age: 18+
Code: NCT06119685
Phase1, Phase2, Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for
Carcinoma, Non-Small Cell Lung,
Location: Nashville TN, Indianapolis IN, Springfield IL,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT04389632
Phase1, Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
for
Metastatic Solid Tumor, Advanced Solid Tumor,
Location: Nashville TN, Denver CO, Columbus OH, New Lenox IL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06561685
Phase1, Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
for
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma,
Location: Nashville TN, Atlanta GA, Athens GA, St Louis MO,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06827236
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
for
Advanced HR+/HER2- Breast Cancer,
Location: Nashville TN, St Louis MO, Toronto, Houston TX,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06726148
Phase1, Phase2, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for
Extensive-Stage Small Cell Lung Cancer
Location: Nashville TN, Marietta GA, Cincinnati OH, Peoria IL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06646276
Phase3, Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
for
Refractory Diffuse Large B Cell Lymphoma (DLBCL),
Location: Nashville TN, Birmingham AL, Atlanta GA, St Louis MO,
Sponsor: Miltenyi Biomedicine GmbH
Sex: All
Age: 18+
Code: NCT04792489
Phase2, Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
for
Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer,
Location: Nashville TN, Louisville KY, Greenville SC, Chicago IL,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT05983432
Phase1, Recruiting
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
for
HR+/HER2-negative Breast Cancer
Location: Nashville TN, Chicago IL, Fairfax VA, Flower Mound TX,
Sponsor: Totus Medicines
Sex: Female
Age: 18+
Code: NCT05683418
Phase1, Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Location: Nashville TN, Louisville KY, Atlanta GA, Augusta GA,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT05735184
Phase1, Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
for
Locally Advanced Solid Tumor
Location: Nashville TN, Urbana IL, Chicago IL, Zion IL,
Sponsor: Tango Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05732831
Phase1, Phase2, Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Location: Nashville TN, Atlanta GA, St Louis MO, Columbus OH,
Sponsor: Nuvalent Inc.
Sex: All
Age: 12+
Code: NCT05384626
Phase1, Phase2, Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
for
Graft-versus-host Disease (GVHD)
Location: Nashville TN, Atlanta GA, Indianapolis IN, St Louis MO,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT06615050
Phase3, Recruiting
Multi-Institutional Registry for Prostate Cancer Radiosurgery
for
Prostate Cancer Early Risk Treated by Radiosurgery,